Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences ...

PARSIPPANY, NJ, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics ®, a subsidiary of Interpace Biosciences ®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the ...

--Interpace Biosciences, Inc., a leader in leveraging molecular diagnostics and other platforms for the benefit of patients and supporting pharmaceutical development, today announced that it has ...

PARSIPPANY, NJ, May 08, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended ...

PARSIPPANY, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides ...

Interpace Diagnostics Group Inc., a Parsippany-based diagnostic testing and services company, announced Monday that it has extended its agreement with global life sciences firm LabCorp for two years.

Comms outreach efforts pass the test for Interpace . A combination of traditional and modern comms tactics help molecular diagnostic testing company Interpace craft messages that resonate with all key ...

Colorado-based Flagship Biosciences, which focuses on spatial biology and biomarker analytics services, acquired Interpace Biosciences’ Pharma Solutions (IPS) division for an undisclosed price.

Investment expected to support achieving cash flow break-even and accelerate Interpace’s growth plans and acquisition strategy Parsippany, NJ, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Interpace ...